Cordlife (CBB)

Shares / Stock Code

CCB

Stock Exchange / Sharemarket

Australian Securities Exchange

Cordlife (CBB) core business is in adult stem cell therapeutics and cell-based products and services. Each of the group operating businesses is currently revenue generating. The company owns a portfolio of patented stem cell expansion technology for supporting cellular transplantations, as well as T-cell production technology for restoring the immune system. These technologies will enter clinical trials in 2006 and will evolve to clinical therapeutic products.

The company was listed on the ASX in June 2004. With its head office in Australia, CyGenics operates three divisions: Singapore-based CordLife (tissue banking services) and Cell Sciences (consumable cell products), and Cytomatrix (cell therapeutics and technology development) based in the USA. Cygenics Ltd was renamed to Cordlife Limited in April 2007.

CordLife operates Australasia's largest network of private cord blood banks with full processing and cryopreservation storage facilities in Singapore, Hong Kong, Indonesia and India as well as marketing presence throughout the region. CordLife is listed on the Australian Stock Exchange as 'CBB'. In a short span of 8 years, CordLife has grown to become the leading cord blood bank which over 24,0001 families chose to trust.

CordLife collects, processes and stores cord blood stem cells which may later become potential source material for lifesaving treatment. They provide families with high quality cord blood processing and storage services to protect their children's cord blood stem cells. Cord blood has become a major source of stem cells for transplantation worldwide since the first transplant in 1988. Doctors have used cord blood stem cells to treat more than 14,000 patients suffering from over 80 diseases including certain cancers and bone marrow failure syndromes, inborn errors of metabolism, blood disorders and immunodeficiencies.

Since their inception in 2001, they have established a rigorous quality system and track record of clinically reliable cord blood banking service that was first certified by Singapore's Ministry of Health, and subsequently accredited in 2005 by the world's most recognised quality standards in cord blood banking - American Association of Blood Banks (AABB).

Cordlife Group of companies all over Asia have also attained numerous accreditations and certifications from other quality organisations such as the Therapeutic Goods Administration (TGA), International Organization for Standardization (ISO), and local regulators such as the Ministry of Health (Indonesia) and Ministry of Health (India) to give their clients the added assurance that their baby's cord blood will be collected, processed and stored according to stringent quality standards to deliver safe stem cells for medical treatment. The company's ability to obtain various local and international quality marks and regulatory certifications is testimony of the company's intimate knowledge of the cord blood banking industry and its needs.

In 2006, CordLife was awarded the prestigious 'Technology Pioneer' status by the World Economic Forum for advancing the field of adult stem cell therapy, cord blood banking and technologies. CordLife was one of the only 3 companies in Asia to be awarded this rare recognition.

Cordlife (CBB) Products and Services

  • Cordlife is a healthcare company focused on tissue and cord blood banking

Cordlife (CBB) Locations and Subsidiaries

Cordlife Head Office
405 Little Bourke Street, Level 2,
MELBOURNE, VIC 3000
Phone: (03) 9600 3522
Fax: (03) 9600 3544

Cordlife (CBB) Share Price

Submitted by ASX Listed Company on 13 March, 2010 - 05:30

Download our FREE App


Signup for Free
Don't miss out on your free share trading articles.


Free Risk Money Management Calculator for those who sign up!